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Toxoplasma gondii, the most common parasitic infection of human brain and eye, persists across 
lifetimes, can progressively damage sight, and is currently incurable. New, curative medicines are 
needed urgently. Herein, we develop novel models to facilitate drug development: EGS strain T. 
gondii forms cysts in vitro that induce oocysts in cats, the gold standard criterion for cysts. These 
cysts highly express cytochrome b. Using these models, we envisioned, and then created, novel 
4-(1H)-quinolone scaffolds that target the cytochrome bc1 complex Qi site, of which, a substituted 
5,6,7,8-tetrahydroquinolin-4-one inhibits active infection (IC50, 30 nM) and cysts (IC50, 4 μM) in vitro, 
and in vivo (25 mg/kg), and drug resistant Plasmodium falciparum (IC50, <30 nM), with clinically relevant 
synergy. Mutant yeast and co-crystallographic studies demonstrate binding to the bc1 complex Qi site. 
Our results have direct impact on improving outcomes for those with toxoplasmosis, malaria, and ~2 
billion persons chronically infected with encysted bradyzoites.
Toxoplasma gondii infections can cause systemic symptoms, damage and destroy tissues1–10, especially eye and 
brain1–10 and cause fatalitiesS1–20. Primary infections may be asymptomatic, or cause fever, headache, malaise, 
lymphadenopathy, and rarely meningoencephalitis, myocarditis, or pericarditis9,11,12. Retinochoroiditis and reti-
nal scars develop in up to 30% of infected persons1,7,13, and epilepsy may occur6,14. In immune-compromised and 
congenitally infected persons, active infection frequently is harmful1–10. Recrudescence arises from incurable, 
dormant cysts throughout life6,7,9,10. In rodents, chronic infection alters fear, smell, reward pathways, neurotrans-
mitters such as GABA and dopamine, and causes abnormal neurologic functions15. Although this parasite is 
present in the brains of 2–3 billion persons worldwide, consequences are unknown. Neurobehavioral abnormal-
ities and differences in serum cytokines, chemokines, and growth factors were associated with seropositivity in 
humans16,17. Estimates of costs for available suboptimal medicines to treat active, primary ocular, gestational, and 
congenital infections, in just the U.S. and Brazil, exceed $5 billion per year (Table 1).
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Table 1. Cost Analysis of Treatment. Note: Immune compromised not reported, assume cost similar to 
mothers multiplied by number of unknown cases. aCost of medicines, manufactured in the United States, prior 
to August 2015.  bApproximately 1/3 of infected mothers transmit to the fetus. cCost analysis data for Brazil 
provided by Eleonor G.Lago, MD, PhD
Current treatments against active T. gondii tachyzoites can have side effects such as hypersensitivity, kidney 
stones, and bone marrow suppression, limiting their use10. Latent bradyzoites are not significantly affected by 
any medicines6. Atovaquone partially, and transiently, limits cyst burden in mice18, but resistance develops with 
clinical use19–24. Thus, T. gondii infection is incurable with recrudescence from latent parasites posing a contin-
ual threat. Improved medicines are needed urgently. Molecular targets shared by T. gondii and Plasmodia make 
re-purposing compounds a productive strategy.
Critical flaws and limitations of available methods and models for developing medicines to cure T. gondii 
infections include lack of in vitro culture systems for cysts and scalable, easy to use animal models for screening 
compounds. To address these challenges, we characterized the EGS parasite (Fig. 1), isolated in 1994 from amni-
otic fluid of a congenitally infected Brazilian fetus25, that form cyst-like structures in vitro. In our characterization 
of EGS in vitro, herein, we discovered that true cysts develop, making EGS especially useful for drug development. 
EGS parasites can infect zebrafish, and we have characterized this, as well as a fluorescent tachyzoite and cyst 
assay in this new model26. Further, cytochrome bc1 expression is markedly increased in encysted EGS bradyzoites 
suggesting cytochrome bc1 might be a viable drug target for this life stage. This mitochondrial membrane bound 
protein complex cytochome bc1, part of the electron transport chain responsible for generating ubiquinone for 
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Figure 1. Characterization of Brazilian (TgBr EGS) T. gondii, originally isolated from amniotic fluid in 
1994, establishes novel in vitro model. (a) In vitro EGS cultures in HFF cells form cysts. Note green dolichos 
immunstaining of the perimeter cyst wall, red bradyzoite antigen 1 (BAG1) immunostaining, and blue DAPI 
staining of DNA. These cultures produce oocysts when fed to cats (see Fig. 2). (b) Genetic characterization of 
EGS strain. Neighbor-net analysis based on 790,168 genome-wide SNPs common to EGS strain plus 62 parasite 
isolates representing all major population haplogroups that have been described for T. gondii demonstrated that 
EGS belongs to clade B, haplogroup 4. Groups A to F indicate major population clades of T. gondii. Haplogroup 
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pyrimidine biosynthesis in Plasmodium, is the molecular target of the naphthoquinone, atovaquone27–52. Partial 
efficacy, rapid emergence of drug resistance in malaria and toxoplasmosis limit clinical usefulness of atovaquone. 
We present new 4-(1H)-quinolone scaffolds that target the Qi site of cytochrome bc1 in apicomplexan parasites. 
Our lead 5,6,7,8-tetrahydroquinolin-4-one compound, MJM170, is highly effective against apicomplexan para-
sites and has substantially enhanced solubility compared with other reported quinolones due to its’ new scaffold. 
Direct visualisation in the crystallographic structure opens the way to design a new generation of compounds for 
both parasites.
Results
Characterization of EGS strain develops novel in vitro models to test compounds 
Genotyping and Phylogenetic Analysis of EGS. We isolated and sequenced genomic DNA from the EGS25 
parasite, which formed cysts when grown in human foreskin fibroblasts (HFF) in culture, Fig. 1a (left 
panel). Phylogenetic analysis based on 796,168 SNPs across 62 T. gondii genomes revealed that EGS is 
closely related to other Brazilian strains including TgCatBr1, TgCatBr18 and TgCatBr25 and ancient South 
American MAS (Fig. 1b). All these grouped to clade B, haplogroup 4 and 8. EGS differs from other iso-
lates by non-synonymous SNPs in Apetela 2 IV-iv, M= > I (570) and a disordered area beginning at 821, 
GGNRPHYHVAKQEWRVRYYMNGKRKMRTYSAKFY GYETAHTMAEDFAHYVDKHE. AP2 IV-iv is 
a member of the plant-like transcription factor family unique to apicomplexan parasites. This AP2 represses 
bradyzoite to tachyzoite conversion, among other differences (Table 1; Fig. 1c; Supplement A: Box and Figure S2, 
Supplement B: Excel Table S1).
Phenotypes of EGS in Human cells in vitro, and in Cats and Mice 
EGS in human foreskin fibroblasts (HFF). In vitro, these EGS parasites form cysts that enlarge over ~96 hours 
and then destroy monolayers as single cell organisms (Fig. 1d). This created novel, useful in vitro models. Cyst 
walls are thick in electron micrographs (data not shown). Cyst-like structures’ perimeters demonstrate dolichos 
(green), with bradyzoites within them staining with BAG1 (red) and nuclei with Dapi (blue), Fig. 1a. Kinetic 
analysis of EGS in HFF cultures, 2, 18, and 72 hours after infection, RNA-seq and MiR-seq results demonstrated 
varied expression signatures over time in culture (Fig. 1e and Supplement B: Excel Tables S2 and S3) with expres-
sion of bradyzoite markers by 18 hours and Apetela 2 signatures by 2 hours.
Cats fed EGS in HFF cultures or mouse brain produce oocysts. When HFF tissue cultures with these cyst struc-
tures as seen in Fig. 1a were fed to cats, they developed the classic, gold standard bradyzoite phenotype of produc-
ing oocysts (Fig. 2) in two replicate experiments. All other T. gondii strains cultured for more than 30 passages, as 
EGS was since the 1990s, lose the ability to produce oocysts when fed to cats (JP Dubey, personal observations, 
1975–2015). This experiment established that these were true bradyzoites in cysts formed in vitro under standard 
culture conditions. Oocysts also formed 10 days after feeding cats mouse brains infected with EGS stably trans-
fected with tachyzoite SAG1 promoter-driven mcherry, and bradyzoite BAG1 promoter-driven green fluorescent 
protein (GFP), and merozoite promoter-driven blue fluorescent protein, engineered to facilitate creation of auto-
mated, scalable in vitro and in vivo assays. In vitro, these promoters did not provide a fluorescence signal robust 
enough to detect differences between 2 × 105 and 650 parasites useful in scalable assays (data not shown).
EGS is virulent in Mice. When these EGS oocysts were fed to mice they produced disease indistinguishable from 
other virulent Brazilian strains. Oocysts given to mice per-orally created an illness and histopathology pheno-
typically characteristic for typical, virulent parasites causing dose related proliferation of T. gondii with necrosis 
in terminal ileum, pneumonia at 9–10 days, with brain parasites by 17 days and dose-related mortality (Fig. 2).
EGS has a bradyzoite/cyst morphology and alters the transcriptomes of the biologically relevant human monocytic cell 
line MM6 and human primary neuronal stem cells (NSC). Human cells particularly relevant to human toxoplas-
mosis were infected with different strains of T. gondii to better characterize EGS parasites. Immunofluorescence 
staining of EGS-infected MM6 and NSC cultures revealed the development of cysts (Fig. 3a) and accordingly, 
EGS gene expression resembled that of bradyzoites when compared to equivalent infections done with GT1, 
ME49 or VEG strains. Interestingly, EGS transcription was influenced by host cell type (Fig. 3). Transcriptomics 
numbers are indicated within parentheses based on previous designation. Names within red rectangles denote 
the representative strains from each haplogroup. (c). Full genome sequence analysis of EGS compared with 
canonical and geographically closely related parasite genomic sequences reveal a non-synonymous mutation 
and disordered c terminal sequence in Apetela 2(AP2) IV-iv, a bradyzoite repressor. Because AP2 IV-iv is 
a bradyzoite repressor, a mutation could create a parasite like EGS that remains as an encysted bradyzoite. 
Biological process GO representation among EGS genes carrying non-synonymous SNPs not present in other 
canonical and phylogenetically closely related parasite genomic sequences. This analysis revealed unique non-
synonymous SNPs in Apetela 2 transcription factor genes and other genes shown in Supplement A: Figure S1 
and Supplement B: Excel Table S1 which shows the Go Slim Analysis. The effect on transcription may reflect 
the disordered region and nonsynomous mutation in AP2 IV-iv. (d) Cysts of EGS enlarge with time in culture 
in HFF. This enlargement is visible over the initial 96 hours in culture. (e) DGE analysis of EGS cultures in HFF 
reveals changes over time in both host and parasite transcriptomes. Left and middle panels depict heat maps 
of the 50 most upregulated HFF and EGS genes respectively. Right panel: MDS plot of HFF gene expression 
profiles from uninfected human fibroblast or infected with EGS parasites for 2, 18 or 48 hours. The full data set 
is in Supplement B: Excel Table S2.
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Figure 2. EGS is the only T. gondii cultured for more than 30 passages demonstrated to form an encysted 
bradyzoite when cultures of these parasites are tested by gold standard in vivo assay. This EGS given as 
oocysts produced from feeding EGS cysts in HFF to mice behaves as a typical virulent and pathogenic Brazilian 
parasite. The dose related infection of terminal ileum, dissemination to lung, ear and brain, presence of 
tachyzoites and then bradyzoites in multiple organs, and dose related mortality resembles infection of mice with 
other Brazilian strains characteristic of a typical virulent organism.
www.nature.com/scientificreports/
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Figure 3. EGS morphology and effect on host cell transcriptomes. (a) EGS in human MM6 cells and NSC 
form cysts. Left NSC with EGS. Right MM6 with EGS. Note green dolichos cyst walls and BAG1(red) in NSC. 
DAPI stained nuclei(blue). (b–d) Effects of EGS infection on MM6 and NSC transcriptomes: EGS transcripts 
in MM6 compared with NSC shows overlap of, as well as unique patterns of, transcripts. Differentially 
expressed genes in MM6 and NSC cells infected with EGS parasite were identified based on criteria of 1% FDR 
and absolute fold-change ≥ 2. Number of DEGs in each cell line are presented with bar graph (b) and Venn 
diagram are used to show general comparison of DEGs identified between the two cell lines (c). There is both 
commonality, overlap in genes modulated and independence in others between cell types indicating cell type 
also influences transcriptome. Red and green colors were used to represent up- and down-regulated genes, 
cell line used is indicated on bottom (b–d). Functional enrichment analysis was performed for gene ontology 
(GO) biological process and KEGG pathways (d). P-values derived from analysis were -log10 transformed 
and presented as a heat map. Pink and blue colors indicate GO terms or KEGG pathways enriched by up- and 
down-regulated genes, respectively. Enriched pathways or biological processes are listed on right of panels and 
cell lines are indicated on top. e. Host cell miR-seq analysis reveals that EGS regulates host cell miRNAs critical 
in pathogenesis and latency. Data are in Supplement B: Table S8. An especially interesting down-modulated 
miRNA is hsa-miR-708-5p which is expressed particularly in brain and retina cells causing apoptosis65. When 
T. gondii downmodulates this as an encysted bradyzoite in neuronal cells, it would prevent hosts from initiating 
apoptosis to eliminate chronically infected neurons. (f). Parasite genetics and human host cell type have a 
profound influence on T. gondii gene expression. MDS plot comparing T. gondii gene expression profiles from 
MM6 and NSC cells infected with EGS, GT1, ME49 and VEG strains for 18 hours and HFF cell cultures infected 
with EGS strain for 2, 18 and 48 hours.
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Figure 4. Differential Gene Expression (DGE) analyses and effects of inhibition of cytochrome bc1.  
(a) DGE analysis of bradyzoite- and tachyzoite-specific markers during EGS infections of HFF cultures at 2, 
18 and 48 hours (top panel), MM6 cells at 18 hours (middle panel) or NSC cultures at 18 hours (bottom panel) 
versus infections of same host cells with canonical strains GT1, ME49 or VEG at 18 hours (averaged across the 
three canonical strains for HFF infections). Genes reported as being over- or under-expressed during bradyzoite 
differentiation is indicated with red or green arrows respectively. “* ”, q-value ≤ 0.05; LogFC, logarithm of 
the fold change in gene expression. CST1, SAG-related sequence SRS44s114; LDH2, lactate dehydrogenase 
2S115; LDH1, lactate dehydrogenase 1S115; ENO2, enolase 2; ENO1, enolase 1S116; SAG1, SAG-related sequence 
SRS29B; BAG1, bradyzoite antigen BAG1S115. (b) DGE analysis of genes encoding AP2 family of transcription 
factor during the same infection experiments as described in (a). Red and green arrows denote AP2 genes found 
to be over- or under-expressed during bradyzoite developmentS117. “* ”, q-value ≤ 0.05. (c) T. gondii cytochrome 
family genes differentially expressed during same experimental infections as described in (a). “*”, q-value ≤ 0.05. 
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using host mRNA and miR profiling of EGS cultures in MM6, and NSC cells for 18 hours demonstrated that this 
parasite modulates host transcripts involved in protein misfolding, neurodegeneration, endoplasmic reticulum 
stress, splicesosome alteration, ribosome biogenesis, cell cycle, epilepsy, and brain cancer among others (Fig. 3 
and Supplement B: Excel Tables S4–S8). The number of genes significantly up or down regulated in MM6 and 
NSC cells compared to uninfected controls are depicted in Fig. 3. Overexpressed genes differ from those of GT1, 
ME49 and VEG tachyzoite-infected human NSC cells (Fig. 4a), but modify the same or connected pathways 
(McLeod et al. unpublished observations). Hsa-miR-708-5p was the most affected miRNA (down-modulated) by 
EGS (Fig. 3; Supplement B: Table S8). miR-708-5p is a regulator that promotes apoptosis in neuronal and retinal 
cells, which could maintain a niche for EGS-like encysted bradyzoites to persist.
EGS transcripts demonstrate importance of cytochromes and key Apetela 2 transcription factors in this life cycle 
stage. EGS transcripts in HHF, MM6, and NSC cells were enriched for genes transcribed in bradyzoites, 
including known bradyzoite transcripts, certain Apetela 2s and cytochrome b and other cytochromes (Fig. 4b,c). 
Among transcripts with the most increased fold change in EGS across all three cell lines were: cytochrome b; 
cytochrome c oxidase subunit III subfamily protein; apocytochrome b; cytochrome b, putative; and cytochrome 
b (N-terminal)/b6/petB subfamily protein. Other over-expressed genes include bradyzoite transcription factor 
AP2IX-9 and plant-like heat-shock protein BAG1 (Fig. 4a–c).
Identifying novel and efficacious compounds against T. gondii cytochrome bc1. Increased 
expression of cytochromes in EGS (Fig. 4c) made it pertinent to synthesize and test an endochin-like quinolone 
(ELQ) 271, which was previously reported to inhibit T. gondii cytochrome bc1 Qi site and reduce, but not elimi-
nate, brain cyst numbers in mice27. ELQ271 also inhibited EGS in vitro (Fig. 4d bottom) demonstrating that our 
in vitro model correlates with previously reported partial activity of ELQ271 against bradyzoites in cysts in mouse 
brain. Vivoporter-PMOs inhibiting cytochrome bc1 had a modest effect on tachyzoite replication and a small 
effect on size and number of EGS cysts (Fig. 4d top). Minimal effect might be related to limited entry of vivoporter 
into cysts or mitochondria.
ELQs have been a focus for drug development for malaria (ELQ 300) and toxoplasmosis (ELQ 271 and 316) 
as they were reported to be potent and selective (versus human cytochrome bc1) inhibitors of P. falciparum 
cytochrome bc1 at nanomolar concentrations27. ELQs are part of the 4-(1H)-quinolone class of cytochrome bc1 
inhibitor36,40,42,45,49,52–61 and (Doggett et al., 13th International Toxoplasmosis Meeting Abstract. Gettysburg 
Pennsylvania, June 2015), a scaffold that suffers from limited aqueous solubility. Another critical aspect of inhib-
itor design for this system is minimizing the inhibition of mammalian cytochrome bc1, which shares ~40% 
sequence identity to the T. gondii ortholog within the Q substrate sites. Thus, we set out to design potent and selec-
tive inhibitors of T. gondii cytochrome bc1 with improved solubility (Fig. 5) compared to known quinolone-based 
inhibitors. Noting the previous work of GSK on the preclinical development of Clopidol derivatives which led to 
terminating studies secondary to toxicity in the rat models, as another serious deficiency62 and the incorporation 
of the diphenyl ether group onto the central 4-(1H)-quinolone core as reported by Riscoe et al.27, we focused 
on the central core ring system. Doggett, Riscoe et al.’s27 ELQ 271 (Figs 1 and 5) was reported to be ineffective 
against yeast with a mutation in the Qi site. Nonetheless, it recently was shown that ELQs can bind both Qi and 
Qo depending on subtle chemical changes60–62. As a result of our initial efforts, a 5,6,7,8-tetrahydroquinolone 
(MJM170, 2) displayed promising results. (Fig. 5; Table 2). We chose ELQ271 for comparison because it had the 
greatest activity at the lowest dose (5mg/kg) in the mouse model of Doggett despite the higher cytotoxicity toward 
human fibroblasts in the in vitro toxicity studies27.
MJM170 is a potent inhibitor of T. gondii tachyzoites (RH-YFP strain, IC50 0.03 μ M) and bradyzoites (EGS 
strain, IC50 4 μ M), equipotent to ELQ271 (Table 2, Fig. 6).
MJM170 showed 10-fold improved aqueous kinetic solubility (pH 7.4) over ELQ 271 (Table 2), 3-fold 
improved FaSSIF (pH 6.5) solubility, with similar human microsomal stability profiles (146 vs 172 minutes). A 
different method from that in ref. 49 was used. MJM170 has a significantly decreased mouse microsomal stability 
compared to ELQ 271 (20 vs > 200 minutes). MJM170 was further evaluated with MDCK-MDR1 cells (a measure 
of blood-brain barrier permeability) and results suggest that MJM170 could cross the blood brain barrier and 
not suffer from P-glycoprotein efflux These data highlight the potential of the 5,6,7,8-tetrahydroquinolin-4-one 
scaffold for further hit-to-lead development.
MJM 170 is effective in vivo against tachyzoites, and modestly against bradyzoites in cysts of 
mice, and development of a scalable zebrafish assay. MJM170 was highly efficacious against RH 
(Fig. 7a) and Prugniaud (Fig. 7b) strain tachyzoites in mice at 25 mg/kg without toxicity for 5 days (p < 0.00), 
and modestly reduced numbers of Me49 strain cysts established > 2months earlier when treated with 12.5–25 mg 
(d) Effect of known cytochrome b inhibitors on EGS. Morpholino conjugated to a Vivoporter (called PPMO) 
designed to knock down cytochrome b compared with off target control has a significant effect in reducing 
replication of YFP RH strain tachyzoites at 5 and 10 μ M (p < 0.05) but only a very small effect on size and 
number of EGS cysts in HFF. As a poorly soluble inhibitor of cytochrome b, ELQ271 was reported to partially 
reduce cyst numbers in mice27 and is shown herein also to reduce the EGS cysts in vitro at 10 μ M in this novel 
model. This demonstrates the utility of this novel in vitro model by indicating that inhibition of cytochrome b 
Qi is associated with reduction of cysts in vivo in a mouse model, even when there are serious limitations caused 
by insolubility of this inhibitory compound. This poor solubility significantly limits ELQ271 as a candidate for 
progression to a medicine. Increasing selectivity for the parasite enzyme with our new scaffold is another critical 
challenge.
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mg/kg for 17 days (p < 0.002) (Fig. 7c). In analysis of parallel histopathology, there was a similar trend (data not 
shown). Translucent zebra fish can be infected with EGS, other T. gondii that make cysts, and RH YFP preparing 
for a novel model for scalable screening (Fig. 7d).
Cytochrome bc1 Qi is the binding site of MJM170 which is potent against Plasmodium falci-
parum and yeast. Tetrahydroquinolone binds to the Qi site of cytochrome bc1. Studies to determine whether 
cytochrome bc1 Qi is the molecular target of MJM170 initially included studies of resistance of yeast and P. falci-
parum with known cytochrome b Qi mutations predicted to cause a steric clash with MJM170 (Fig. 8). Recently, 
we reported co-crystal structures of GSK’s cytochrome bc1 inhibitors bound to bovine cytochrome bc1 at the Qi 
Figure 5. (a) Structures of the ELQ class (1–3) and the tetrahydroquinolone scaffold (4)27,45,49,53 . Low solubility 
of the ELQs has been a serious concern going into preclinical evaluation for treatment of malaria27. (b) 
Saccharomyces cerevisiae cytochrome bc1 X-ray structure (PDB ID: 1KB9)5 The complex contains 11 subunits 
and 3 respiratory subunits (cytochrome b, cytochrome c1 and Rieske protein). The cytochrome b subunit 
provides both quinone binding sites (Qo and Qi) highlighted as grey and pink surfaces respectively.
Compound ELQ 271 MJM170
Structure
Mol. Wt. 411.4 331.4
T. gondii Tachyzoite IC50 μ M 0.03 0.03
T. gondii Bradyzoite IC50 μ M 1 4
P. falciparum IC50 μ Ma 0.03 (D6) 0.09 (TM91C235) 0.10 (W2) 0.13 (C2B) 0.01 (D6) 0.03 (TM91C235) 0.03 (W2) 0.01 (C2B)
HFF Toxicity CC50 μ M 20 20
Kinetic Solubility PBS pH 7.4 μ Mb 0.15 1.97
FaSSIF Solubility pH 6.5 μ Mb 3.4 9.8
Human microsomal stability T1/2 minsb 171.9 146.3
Mouse microsomal stability T1/2 minsb > 200 21.0
MDCK-MDR1 PappA-B × 106 cm/sb N.D. 32.1
MDCK-MDR1 Efflux Ratiob N.D. 1.23
Table 2. Comparison of ELQ 271 and MJM170 in our biological assays: inhibition of apicomplexan 
parasites and ADME/Tox. ELQ 271 was synthesised in-house. aThe D6 strain (Sierra Leone) is drug sensitive, 
the TM91C235 (Thailand) is multi-drug resistant, the W2 strain (Thailand) is chloroquine resistant, and 
the C2B strain is multi-drug resistant with pronounced resistance to atovaquone. bADME carried out by 
ChemPartner Shanghai Ltd. N.D. not determined. Human and mouse microsomal stability differs as is known 
to occur for other compounds such as TMP/SMX.
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site52 demonstrating that these pyridone inhibitors and other structurally related inhibitors bind to an alternative 
site to atovaquone on cytochrome bc1. This structure allowed us to model MJM170 within the Qi site using the 
Maestro Suite from Schrödinger. This molecular modelling predicted steric clashes in mutant yeast and P. falci-
parum cytochrome bc1 with MJM170 (Fig. 8a).
Figure 6. ELQ inhibitors provide a new scaffold and approach yielding compounds that are potent 
inhibitors of tachyzoites and cysts in vitro. (a–e) Study of Inhibitors in vitro is summarized in Table 2 and 
led to selection of MJM170 as a promising novel scaffold for both tachyzoites and bradyzoites. (a) MJM170 
markedly reduces RH YFP tachyzoites in tissue culture robustly at low nanoM levels. (Standard curve left and 
effect on RH YFP, right panel). (b,c) MJM170 markedly reduces EGS bradyzoites in cysts in vitro. Inhibition of 
cytochrome b Qi eliminates cysts in HFF infected with EGS. Without inhibitory compound in HFF (note, oval 
cyst with green border staining dolichos) and adjacent panel with inhibitory MJM170 compound (note absence 
of cysts with small amount of amorphous residual dolichos). MJM170 eliminated tachyzoites followed to 10 
days of culture and bradyzoites in cysts in vitro. Summary comparison of each of the compounds tested in vitro 
and their ADMET is in Table 2. Note improvement in solubility, properties amenable for compounds to cross 
blood brain barrier with new scaffold. (d) EGS transfected with stage specific reporters for fluors, red tachyzoite 
SAG1, Green bradyzoite LDH2.
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Co-crystallization of MJM170 with bovine cytochrome bc1 and modelling of the T. gondii enzyme confirm the target. 
Co-crystallization validates predictions made with modelling and confirmed using assays with S. cerevesiae 
mutants (Fig. 8d). There was no steric clash for P. falciparum- model based upon this crystal stucture, consistent 
with in vitro assays (Fig. 8e,f). MJM170 was co-crystallized with bovine cytochrome bc1 (Supplement A: Box 
with co-crystallography data) and the resulting good quality electron density maps allowed for unambiguous 
placement of MJM170 within the Qi site (Fig. 8f). The planar region of the quinolone group is held between heme 
bH and Phe220 and the additional ring further extends into the hydrophobic cavity at the apex of the binding site 
towards Pro24 and Ile27. The carbonyl group of the compound is surrounded by Ser35, Asp228 and the carbonyl 
of Trp31, while it’s amine moiety lies between His201 and Ser205. The diphenyl ether group extends outwards 
Figure 7. MJM170 is also effective against RH and Prugniaud tachyzoites and Me49 bradyzoites, in vivo 
with translucent zebrafish providing a novel model with potential for scalable in vivo assays in which 
tachyzoites with fluorescent reporters and bradyzoites in cysts can be visualized efficiently. (a) 25 mg/kg  
daily MJM170 administered intraperitoneally eliminates active infection due to RH tachyzoites stably 
transfected with YFP in mice (RFU control vs rx with MJM 170, p < 0.004) . For the standard curve in the inset, 
RFU increase with increasing concentrations of fluorescent tachyzoites (R2 = 0.99). (b) MJM 170 25 mg/kg daily 
reduces Type 2 parasites. (c) MJM 170 reduces cysts in mice infected 2.5 months earlier and treated for 17 days 
with 12.5 mg/kg daily then without compound for 3 days:cyst count of wet prep of brain homogenate. (d) Zebra 
fish can be used to visualize fluorescent tachyzoites and cysts in more chronic infections.
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Figure 8. MJM170 targets apicomplexan cytochrome bc1 Qi : modelling, yeast surrogate assays, target 
validation, co-crystallography and nanoM inhibition of P. falciparum and T. gondii. (a) Modeling: MJM170 
(yellow) modelled within cytochrome b Qi site (grey) highlighting residues (green) involved in binding.  
(b) Mutations for yeast, P. falciparum, predicted for T. gondii and bovine enzyme. Relevant mutations are 
indicated by colored dots in Qi domains on the bottom of the image of mitochondrion membrane for  
S. cerevesiae and P. falciparum, and where those amino acids are in T. gondii, human and bovine enzymes. Red 
dot marks G33A/V in Qi domain of P. falciparum. (c) Cytochrome b mutants and sequence accession numbers. 
(d) MJM 170 inhibits wild-type but not mutant yeast. Compounds MJM 170 and ELQ 271 with wild type and 
mutant yeast validate predictions that M221 K/Q would create a steric clash and resistance. (e) MJM170 is 
a potent low nM inhibitor of Plasmodium falciparum. In Table 2, wild type P. falciparum also are tested and 
is inhibited at < 50 nM by this scaffold. D6 is a drug sensitive strain from Sierra Leone, C235 is a multi-drug 
resistant strain from Thailand, W2 is a chloroquine resistant strain from Thailand, and C2B has resistance to a 
variety of drugs including atovaquone. Mutant G33V did not confirm prediction of a steric clash. (f) MJM170 
binds within Qi site of bovine cytochrome bc1 as shown by X-ray crystallography. (f(i)). An omit Fo-Fc electron 
density map (green) at 5σ allows unambiguous positioning of MJM170 (magenta) within the Qi site with the 
tetrahydroquinolone group near heme bH (white) and diphenyl ether directed out of the channel. (f(ii)) MJM 
170 molecule is included into the structure, the 2Fo-Fc electron density map at 1σ (grey) allows placement of 
the planar head between heme bH and Phe220 with the carbonyl group positioned in a polar region surrounded 
by Ser35 and Asp228. (g) A stereo picture of the 2Fo–Fc electron density map. Electron density at 1σ level 
around cytochrome b α -helixes 118–128 and 183–199 close to MJM180 compound in X-ray structure of 
cytochromebc1. Inset: Crystal of mammalian cytochrome bc1 complex.
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Figure 9. MJM170 potently inhibits P. falciparum mitochondrial electron transport important for 
synthesis of pyrimidines, is modestly synergistic with atovaquone, additive with cycloguanil and 
antagonistic with Qi inhibitor. (a) MJM170 is highly potent (Dd2, black curve, EC50 = 29.5nM) without cross-
resistance in previously reported cytochrome b drug-resistant mutant parasite lines including ubiquinone 
reduction site mutantsS76,S77 (Dd2G33A and Dd2G33V, light blue and dark blue curves, respectively). Dose-
response curve from representative assay. MJM170 cannot inhibit a parasite supplemented with a yeast 
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towards the hydrophobic residues Ile39 and Ile42 and forms a stacking interaction with Phe18 (Fig. 8f). An exam-
ple of a stereo electron density involving Ile118-Met129 and Phe183-Phe199 is shown in (Fig. 8g).
Surrogate assays demonstrate efficacy of compounds, providing target validation and added value as MJM170 is 
effective against wild type but not M221Q(F) mutant yeast. Mutants of S. cerevesiae were used to further confirm 
the molecular target of MJM170 (Fig. 8d), and documented that the Qi domain in cytochrome b is essential for 
its efficacy. This approach provided insight into binding of compounds to the enzyme. Crystallographic struc-
ture of bovine cytochrome bc1 with GSK93212152 indicates that certain amino acids are critical in tetrahydro-
quinolone binding and explains why there is inhibition by certain compounds. Previous studies reported that no 
cross-resistance is observed between ELQs and atovaquone in P. falciparum. This is rationalised as atovaquone 
binds the Qo site on cytochrome bc1. A yeast M221Q substitution within the Qi site displayed resistance to ELQ 
inhibition further confirming that this to be the target site27. MJM170 and ELQ271 were effective against S. 
cerevisiae wild type parental AD1-9 strain at 1mM, 100, 5 and 1 μ M when grown on non-fermentable, glycerol 
medium forcing reliance on ATP production for respiration. Yeast strains with point mutations in the cytochrome 
b gene that substitute methionine by glutamine (M221Q) or phenylalanine (M221F) at position 221 in the Qi site 
predicted to yield a steric clash upon inhibitor binding were resistant to MJM170 (Fig. 8d).
Tetrahydroquinolones are potent against wild type P. falciparum, and P. falciparum G33A/V and other drug resistant 
mutants but not DHODH mutant. MJM170 is highly effective against P. falciparum (Table 2) including multiple 
strains resistant to available antimicrobials and a cytochrome bc1 Qi mutant (Fig. 9). Resistance against transgenic 
P. falciparum yeast DHODH mutant strain indicates MJM170 affects mitochondria suggesting that the mode of 
action against P. falciparum is through inhibition of electron transport (Fig. 9a).
Potentially clinically useful combinations with tetrahydroquinolone demonstrated in synergy 
studies. To determine whether there might be clinically relevant synergies and additive effects, combina-
tions of MJM170 with other clinically available and useful compounds also were tested. Earlier, we had found 
cycloguanil and related biguanide triazines63 were active against T. gondii tachyzoites and P. falciparum making 
it relevant to test them in combination with MJM170. We observed modest synergy in vitro for atovaquone, addi-
tive effect with cycloguanil, and antagonism with BRD6323, a Qi inhibitor for P. falciparum (Fig. 9b). Combining 
atovaquone with proguanil (active component cycloguanil) as MalaroneR for malaria provides an approach to 
reduce selection of drug resistant plasmodium mutants.
Discussion
The results presented here offer a molecular understanding and therapeutic strategies for one of the most com-
mon parasitic infections of human brain and eye, and that persists across lifetimes in around 2 billion people 
worldwide. We have developed new models to facilitate discovery of curative treatments for toxoplasmosis. We 
have characterized the Brazilian T. gondii isolate called EGS that was known to be morphologically similar to 
encysted bradyzoites in tissue culture. We further validate the cystic nature of these EGS infected cultures, since 
they are able to induce the intra-intestinal life cycle when fed to cats ultimately resulting in oocyst secretion. This 
is the first such description of this phenotype and provides definitive proof that this unique parasite has a true cyst 
phenotype when maintained in vitro. Our data also provide a number of other major conceptual advances on EGS 
by demonstrating the following: (i) Genome sequencing of this EGS isolate demonstrates that EGS has a typical 
Brazilian virulent genotype and phylogeny, (ii) EGS is a haplogroup 4 T. gondii. Consistent with a genotype that 
is known to be pathogenic and virulent for mice, we demonstrate that EGS oocyst induced infection is similar to 
that of other virulent Brazilian parasites. For example, mice fed EGS oocysts demonstrated ileal parasites causing 
necrosis, as well as pneumonitis, encephalitis and systemic infection leading to death. This indicates that the 
ability to form cysts in culture does not alter the pathogenicity of EGS in mice. However, potentially relevant to 
its in vitro bradyzoite phenotype, full genome sequencing revealed that it has nonsynonymous single nucleotide 
cytosolic DHODH (scDHODH, green curve) demonstrating that its primary activity in P. falciparum is to 
inhibit electron transport necessary for pyrimidine biosynthesis. Inset Table. Dose-response phenotypes of 
a panel of P. falciparum cytochrome b mutant parasite lines. EC50 values were calculated using whole-cell 
SYBR GreenS78 assay and listed as mean ± standard deviation of three biological replicates, each with triplicate 
measurements. (b,c) Isobolograms with MJM170 plus atovaquone or cycloguanil or Qi inhibitor BRD6323S76: 
(b) Combinations were with atovaquone (ATV) or cycloguanil (CYG) at multiple fixed volumetric ratios 
(10:0, 8:2, 6:4, 4:6, 2:8, and 0:10) in Dd2 parasites. Slight synergy observed with combinations of MJM170 and 
atovaquone while MJM170 and cycloguanil dosed in combination showed additive effect. Fractional inhibitory 
concentrations (FIC) for each drug were calculated and plotted. Shown is a representative isobologram for 
each combination of compounds. Table below lists FICs for each compound and ratio tested (values are mean 
from three independent assays ± standard deviation). Synergy was defined as a combined FIC < 1.0, addivity 
as FIC = 1.0, and antagonism as FIC > 1.0S79. (c) Isobologram Figure: MJM170 was tested in combination with 
previously reported reduction site inhibitor BRD6323S76 at multiple fixed volumetric ratios (10:0, 8:2, 6:4, 4:6, 
2:8, and 0:10) in Dd2 parasites. Antagonism was observed with combinations of MJM170 and BRD6323 as 
opposed to synergy observed with oxidation site inhibitor atovaquone. Fractional inhibitory concentrations 
(FIC) for each drug were calculated and plotted. Representative isobologram of three independent assays is 
shown. Table below lists FICs for each compound and ratio tested (values are means from three independent 
assays ± standard deviation). Definitions as in (b).
www.nature.com/scientificreports/
1 5Scientific RepoRts | 6:29179 | DOI: 10.1038/srep29179
repeat sequence differences from other Brazilian and canonical U.S. and European parasites which do not share 
its in vitro bradyzoite phenotype. EGS has a non-synonymous mutation in a bradyzoite repressor, Apetela 2(AP2) 
IV-iv, plant like transcription factor. AP2s interact with HATs and HDACs to modulate transcriptional signatures 
in apicomplexan parasites64. This Apetela 2 plant like transcription factor gene is known to drive tachyzoite switch 
by repressing bradyzoite genes. If the observed substitution results in a defective or non-functional molecule, this 
could provide an explanation for the observed bradyzoite phenotype of EGS parasites. This is consistent with 
our findings that EGS in HFF forms cysts by 24 hours, characterized by BAG1, and Dolichos staining at 24, 48, 
and 96 hours after infection. These cysts gradually enlarge until 48–96 hrs in culture, when single T. gondii begin 
to destroy HFF monolayers. These are the cultures of bradyzoites in cysts that when fed to cats ~48 hours after 
infection form oocysts which are virulent in mice, providing definitive proof of an in vitro bradyzoite phenotype 
for the EGS strain of T. gondii.
The transcriptomic studies with this EGS isolate have provided critical insights into host cell mechanisms that 
are a prominent part of the ability of the encysted parasite to persist in this untreatable life cycle stage, and bio-
logic consequences of such persistent infection. RNAseq and miR seq of EGS infected human host cells included 
human fibroblasts, monocytic and neuronal stem cells with this encysted EGS strain parasite. These provide an 
understanding of the types of perturbations of biologically relevant host cells this bradyzoite life cycle stage can 
cause, providing insights into unique aspects of pathogenesis of this infection with untreatable cysts and its conse-
quences. We found that EGS modifies critical host cell pathways. For example we find in vitro modulations of host 
cell pathways in human, primary neuronal stem cells are the same as those associated with modulation of host cell 
replication as seen with malignancies, and in neurodegenerative diseases. Further, it is noteworthy that the level 
of a microRNA that specifies apoptosis in eye and brain cells is markedly down modulated by this EGS bradyzoite 
which would inhibit host protective apoptotic mechanisms allowing parasites to persist in brain and eye without 
a critical protective mechanism. EGS, as an encysted bradyzoite, clearly alters biologic processes including cell 
cycle, cell death, alternative splicing, protein synthesis, protein folding and ubiquitination and down regulates 
hsa-miR-708-5p that specifies apoptosis in neuronal and retinal cells65.
RNA and MiR sequencing and transcriptomic analyses of the EGS parasites also identified molecular tar-
gets that are critical for the bradyzoite life cycle stage in the parasite as well. These molecular targets include 
cytochrome b, as critically increased in dormant, encysted parasites. Cytochrome b was increased along with 
known cyst constituents like enolase 1, Cyst wall protein, Lactate dehydrogenase 2, bradyzoite antigen 1, Apetela 2 
plant like transcription factors not present in animals, such as AP2 IX-ix, and cytochrome oxidase. Our work pro-
vides a new means to identify stage specific molecular targets, and emphasizes that cytochrome bc 1 complex is a 
critical target. The transcriptome of EGS parasites in HFF over time are similar to those of in vivo bradyzoites in 
terms of known critical genes modified. Finally, EGS presents a much-needed assay for identifying novel molec-
ular targets present in bradyzoites in vitro. EGS was also useful to evaluate the effect of inhibitors on encysted 
bradyzoites in vitro.
Recent crystallographic studies with the bovine cytochrome bc1 complex allowed us to rationally design a 
novel compound to target the Qi site of cytochrome b. Our novel compound was designed to address issues 
with poor solubility of existing quinolone/pyridone Qi inhibitors. One of these compounds MJM170, a substi-
tuted 5,6,7,8-tetrahydroquinolin-4-one inhibits active infection (IC50 30 nM) and cysts (IC50 4 μ M) in vitro, and 
in vivo (25 mg/kg). It is predicted to cross the blood brain barrier with no efflux as demonstrated in an in vitro 
MDR1-MDCK permeability assay (Table 2), indicating this class of compounds have promise for treatment of 
central nervous system infections. When we tested MJM170 against wild type and multi-drug resistant P. falci-
parum, we found it was also potent (IC50 < 30 nM against all strains). In combination studies, MJM170 was identi-
fied as additive with cycloguanil and modestly synergistic with atovoquone. Studies of yeast and malaria mutants, 
as surrogate assays, and co-crystallography studies with bovine cytochrome bc1 confirm the mechanism of action/
target for MJM170. The co-crystal structure of MJM170 in complex with bovine cytochrome bc1 reveals a clear 
binding mode within the Qi site. Using homology models of the apicomplexan Qi sites, there are clear differences 
between the binding sites of the apicomplexan and mammalian orthologs which can be used to fine-tune the 
selectivity of our scaffold towards apicomplexan bc1. This is important in moving this work forward since other 
Qi inhibitor programs have reported toxicity due to potential inhibition of mammalian bc162. The larger binding 
pocket of the apicomplexan versus the mammalian bc1 may provide a way forward to increase selectivity. Our 
work provides a conceptual and a practical step change forward that provides a foundation for further testing and 
improvements to efficacy, toxicity, solubility, oral absorption, large animal toxicology that will be needed to reach 
the clinic. Protecting the diphenyl ether side chain of MJM170 would make it less vulnerable to metabolic attack49. 
Our work reported herein not only provides new and important insights into the biology of T. gondii, especially 
the bradyzoite life cycle stage and the remarkable effects of this parasite on its human host’s cells, but also provides 
critical molecular targets and new methods to identify others. Armed with this information, a novel scaffold with 
intrinsically higher solubility than the equivalent quinolone has been designed with holds promise towards devel-
oping a much-needed curative medicine for those with toxoplasmosis, malaria, and ~2 billion persons chronically 
infected with presently incurable, encysted bradyzoites which persist and can recrudesce lifelong.
Methods
All methods were carried out in accordance with approved guidelines set at the University of Leeds by the 
Education & Training Resources office and all experimental protocols were approved by the IRB committees; 
University of Chicago Institutional Animal Care and Use Committee (IACUC) and all experimental protocols 
were approved by the IRB committee; United States Department of Agriculture IACUC and all experimental 
protocols were approved by the IRB committees; J Craig Venter Institute Research ethics committee; University 
of Liverpool UK Office for Research Integrity (UKRIO) and all experimental protocols were approved by the 
IRB committees; Harvard School of Public Health HMS IACUC and all experimental protocols were approved 
www.nature.com/scientificreports/
1 6Scientific RepoRts | 6:29179 | DOI: 10.1038/srep29179
by the IRB committees; The Broad Institute IACUC and all experimental protocols were approved by the IRB 
committees; Walter Reed Army Institute of Research Division of Human Subjects Protection (DHSP) and all 
experimental protocols were approved by the IRB committees; Oregon State University IACUC and all experi-
mental protocols were approved by the IRB committees; Institute for Systems Biology ethics committee; Albert 
Einstein College of Medicine IACUC and all experimental protocols were approved by the IRB committees; 
Strathclyde University Ethics Committee (UEC) and all experimental protocols were approved by the IRB com-
mittees; Institute for Integrative Biology of the Cell IACUC and all experimental protocols were approved by the 
IRB committees, and the Centre national de la recherche scientifique IACUC and all experimental protocols were 
approved by the IRB committees.
Cells and Parasites for work with T. gondii 
Cells. The cells utilized for T. gondii assays included human foreskin fibroblasts (HFF)S1–21, Human MonoMac 6 
cells (MM6)S22,S23, and Neuronal Stem cells (NSC) from a temporal lobe biopsyS24.
Toxoplasma gondii. The strains of T. gondii utilized in this work were: RH-YFP Tachyzoites of the RH-YFP 
strain were passaged in human foreskin fibroblasts (HFF cells)S1–21,S25; EGS-Bradyzoite assays use the EGS 
strainS26,S27, isolated from amniotic fluid of human with congenital toxoplasmosisS1,S26,S27; Other strains used are: 
Me49S28; PrugniaudS14,S15; BeverlyS29; Veg; GT1. All other than EGS are T. gondii tachyzoites. These parasites are 
passaged in HFFS1–21.
Isolation of DNA and RNA. EGS single celled organisms were grown in Human Foreskin Fibroblasts, filtered 
free of host cells. gDNAS30 was isolated and processed for sequencing as described. For isolation of RNA RIN 
scores were > 8.
Gene sequencing, genomics, RNA and MiR sequencing, Systems analysis, Metabolomics. 
Genome sequencing of T. gondii EGS strain. A single Illumina paired-end barcoded library was prepared 
from tachyzoite gDNAS30 with Illumina TrueSeq library preparation kit. The library was then sequenced using 
100 bp pared-end reads in one ninth of a lane of an Illumina HiSeq 2000 machine to generate ~2 Gbp of genome 
sequence.
Single nucleotide polymorphism (SNP) identification and annotation. Illumina genome sequencing reads from 
EGS or downloaded from GenBank SRA database for GT1 (SRR516419), VEG (SRR516406) and TgCatBr1 
(SRR350737) were aligned to the T. gondii ME49 reference genome assembly (ABPA02000000, ToxoDBS31 release 
13.0) with Bowtie2S32 and realigned around gaps using the GATK toolkitS33. SNP calls were done simultaneously 
across all four strains with samtools utility mpileupS34, requiring a minimum SNP coverage of 5 reads and an 
alternative allele frequency of 0.8 or higher, given the haploid nature of these genomes. Thereafter, SnpEffS35 and 
a gff3 file containing the annotation of T. gondii ME49 downloaded from ToxoDB v13.0 were used to classify the 
different types of mutations identified in each strain. Allelic variants that were different between EGS and the rest 
of the strain were considered EGS-specific.
Phylogenetic network analysis. A total of 790,168 single nucleotide polymorphisms spanning the entire T. gondii 
genome from 62 different strains representing all major haplogroups were downloaded from ToxoDB, combined 
with SNP data from the same sites from the EGS strain and directly incorporated as a FASTA file into SplitsTreeS36 
v4.13.1 to generate unrooted phylogenetic networks using a neighbor-net method.
Differential gene expression (DGE) analysis. Total RNA extracted from human cell cultures infected (or not) 
with a number of T. gondii strains for 2 h, 18 h or 48 h was treated with miRNeasy Mini Kit columns (Qiagen) 
following manufacturer instructions to separate mRNA and miRNA fractions. Afterwards, Illumina barcoded 
sequencing libraries were constructed with TruSeq RNA Sample Preparation Kits v2 (Illumina) for mRNA and 
miRNA TruSeq Small RNA Library Preparation Kit (Illumina) for miRNA. Libraries were sequenced as 100 bp 
single reads with Illumina HiSeq 2000 apparatus in pulls of 6 or 9 samples per lane for mRNA (yield ~3 Gbp 
per sample) and miRNA (yield ~2 Gbp per sample) libraries respectively. For protein coding genes, reads were 
mapped to the human (release GRCh38) and T. gondii ME49 strain (ToxoDB release 13.0) reference genome 
assemblies and annotations with CLC Genomic Workbench software (CLC Bio-Qiagen, Aarhus, Denmark) and 
raw read counts per gene were then analyzed with the R package EdgeRS37 using a generalized linear model like-
lihood ratio test to identify genes that are differentially expressed among samples.
For miRNA DGE analysis, reads were depleted of adaptor and primer sequences and mapped to the human 
reference genome assembly (GRCh38) and the miRNA annotation from miRBaseS38 v21 (www.mirbase.org) with 
CLC Genomic Workbench software. Identification of human miRNA genes that are differentially expressed across 
treatments was carried out with EdgeR from raw read counts per miRNA gene using a generalized linear model 
likelihood ratio test.
For both mRNA and miRNA DGE analyses p-values were adjusted for multiple hypotheses testing using the 
False Discovery Rate method. MDS plots and heat maps were generated with the plotMDS tool from EdgeR and 
the R tool heatmap. Differentially expressed genes (DEGs) in MM6 and NSC cell lines infected with EGS parasites 
were identified under the criteria of 1% FDR and absolute log2-fold-change > 1.5 (i.e. fold-change > 2 and < 0.5 
for up- and down-regulated genes, respectively).
Functional enrichment analysis. GO enrichment analyses were performed for up- or down-regulated genes, by 
using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7. GO slim enrichment 
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analysisS38a was performed for genes carrying potential change-of-function mutations in EGS that were absent in 
strains ME49, VAND or TgCatBr1. GO slim database was downloaded from QuickGO provided by EMBL-EBI. 
Using taxonomy id “508771” for the ME49 strain, relevant GO slim terms were retrieved. GO slim enrichment 
analysis was performed with Fisher’s exact test based on the GO slim terms.
Assay for oocyst development in cats. Oocysts were collected from feces of Toxoplasma-free cats 3–14 
days after feeding infected cell cultures or infected mouse brains. Oocysts were separated from feces by sugar 
floatation, sporulated in 2% sulfuric acid by aeration at room temperature for 1 week. After removing sulfuric 
acid oocysts were inoculated orally in to Swiss Webster albino mice. All tissues of mice that died or euthanized 
were studied histologically after staining with hematoxylin and eosin and by BAG1 antibodies to T. gondii as 
describedS39.
Chemical Synthesis
Final compounds had > 95% purity determined by high performance liquid chromatography (HPLC) and 300 
and/or 500 MHz NMR spectrometers. Liquid chromatography-mass spectrometry (LC-MS) and high resolution 
mass spectrometers (HRMS) analytical systems were used to determine integrity and purity of all intermediates 
and final compounds. Chemical synthesis is shown in Fig. 10.
ADME studies of inhibitors. Compounds that were highly effective in vitro (IC50 < 1 μ M) were tested for 
ADME profilingS43–58 by Shanghai ChemPartner Ltd. Initial studies focused on aqueous kinetic solubility pH 7.4, 
microsomal metabolic stability (human and mouse) and Blood-Brain Barrier (BBB) permeabilityS43–58  
(performed with MDCK-MDR1 cells as describedS52).
In Vitro assays
Cytotoxicity Assay. Toxicity Analysis. Lack of toxicity for mammalian host cells was demonstrated first by 
visual inspection of monolayers following giemsa staining, in separate methods by incorporation of a mitochon-
drial cell death reagent called WST we used successfully for this purpose and in separate experimentsS12–15;S18,19.
Toxicity assays were conducted using WST-1 cell proliferation reagent (Roche) as describedS12–15;S18,19. HFF 
were grown on a flat, clear-bottomed, black 96-well plate. Confluent HFF were treated with inhibitory compounds 
at concentrations equal to those being tested in challenge assays. Compounds were diluted in IMDM-C, and 
20 μ l were added to each designated well, with triplicates for each condition. A gradient of 2 fold-decreasing con-
centrations of DMSO in clear IMDM-C was used as a control. The plate was incubated for 72 hours at 37 °C. 10 μ l 
of WST-1 reagent (Roche) were added to each well and the cells were incubated for 30 to 60 minutes. Absorbance 
was read using a fluorometer at 420 nm. A higher degree of color change (and absorbance) indicated mitochon-
drial activity and cell viability.
In Vitro Cellular Assays for Effects on T. gondii
Vivo PMO. Vivo-PMO (Vivo porter linked to morpholinos) to knock down cytochrome b and an off- 
target PPMO (Vivo porter) were utilized at concentrations of 5 and 10 μ M as previously described with 
both cultures of RH-YFP tachyzoites and EGSS14. Morpholino sequence for cytochrome b/c knockdown is 
5′ AGTGTTCTCGAAACCATGCTAACAC 3′ , and for unrelated sequence, off target, is 5′ CCTCTTACCTCAG-
TTACAATTTATA 3′ .
Tetrahydroquinolone Compounds. Compounds synthesized at the University of Leeds were initially prepared 
in 10 mM Stock solutions made with 100% Dimethyl Sulfoxide (DMSO) [Sigma Aldrich], and working concen-
trations were made with IMDM-C (1x, [+ ] glutamine, [+ ] 25 mM HEPES, [− ] Phenol red, 10% FBS) [Gibco, 
Denmark]).
Tachyzoite assays. Type 1 parasites. Human foreskin fibroblasts (HFF) were cultured on a flat, 
clear-bottomed, black 96-well plate to 90% to 100% confluence. IMDM (1x, [+ ] glutamine, [+ ] 25 mM HEPES, 
[+ ] Phenol red, 10% FBS [gibco, Denmark]) was removed from each well and replaced with IMDM-C(1x, [+ ] 
glutamine, [+ ] 25 mM HEPES, [− ] Phenol red, 10% FBS)[Gibco, Denmark]). Type I RH parasites expressing 
Yellow Fluorescent Protein (RH-YFP) were lysed from host cells by double passage through a 27-gauge nee-
dle. Parasites were counted and diluted to 32,000/mL in IMDM-C. Fibroblast cultures were infected with 3200 
tachyzoites of the Type I RH-YFP strain and returned to incubator at 37 °C for 1–2 hours to allow for infection 
S12–15;S18,19;S25. Diluted solutions of the compounds were made using IMDM-C, and 20 μ l were added to each desig-
nated well, with triplicates for each condition. Controls included pyrimethamine/sulfadiazine (current standard 
of treatment), DMSO only, fibroblast only, and an untreated YFP gradient with 2 fold dilutions of the parasite. 
Cells were incubated at 37 °C for 72 hours. The plates were read using a fluorimeter (Synergy H4 Hybrid Reader, 
BioTek) To ascertain the amount of yellow fluorescent protein, in relative fluorescence units (RFU), as a measure 
of parasite burden after treatment. Compounds were not considered effective or pursued for further analysis if 
there were no signs of inhibition at 1 μ M. Data was collected using Gen5 software and analyzed with Excel.
Type II parasites. To test type II parasites, T. gondii ME49 and Prugniaud parasites expressing luciferase or GFP. 
We tested them in vitro and in vivo as we have described.
EGS strain Bradyzoite Assay. HFF cells were grown in IMDM (1x, [+ ] glutamine, [+ ] 25 mM HEPES, [+ ] 
Phenol red, 10% FBS, [Gibco, Denmark]) on removable, sterile glass disks in the bottom of a clear, flat-bottomed 
24-well plate. Cultures were infected with 3 × 104 parasites (EGS strain) per well, in 0.5 mL media and plate 
was returned to incubator at 37 °C overnight. The following day, the media was removed and clear IMDM and 
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Figure 10. Synthesis of tetrahydroquinolones. Synthesis of 2-methyl-5,6,7,8-tetrahydroquinolin-4-one (6) Platinum 
oxide (100 mg, 10 mol%) was added to a solution of 4-hydroxy-2-methylquinoline (5, 1.00 g, 6.28 mmol, 1.00 eq) in glacial 
acetic acid (10.0 ml). The heterogeneous mixture was catalytically hydrogenated under a balloon of hydrogen. After 22 hrs, 
TLC (10% MeOH–DCM) confirmed complete reaction. The mixture was filtered through celite under vacuum, washing 
thoroughly with EtOAc. The filtrate was concentrated and the resulting residue purified by column chromatography (10% 
MeOH–DCM) to give the desired product as a pale yellow oil (917 mg, 5.65 mmol, 89%); Rf 0.14 (10% MeOH–DCM); δH 
(300 MHz, CDCl3) 1.74–1.76 (4H, m, CH2), 2.29 (3H, s, Me), 2.49–2.52 (2H, m, CH2), 2.67–2.70 (2H, m, CH2), 6.16 (1H, s, 
Ar-H); δC (125 MHz, CDCl3) 19.0 (Me), 21.8 (CH2), 22.1 (CH2), 27.1 (CH2), 112.5 (CH), 122.4 (Cq), 146.4 (Cq), 147.0 (Cq), 
178.3 (Cq); Spectroscopic data consistent with literature values (JMC, 1993, 36, 1245–54). Synthesis of 2-methyl-3-iodo-
5,6,7,8-tetrahydroquinolin-4-one (7) Butylamine (6.20 ml, 62.8 mmol, 10.0 eq) was added to a suspension of 2-methyl-
5,6,7,8-tetrahydroquinolin-4-one (6, 1.02 g, 6.28 mmol, 1.00 eq) in DMF (10.0 ml). To this heterogeneous mixture was 
added I2 (1.60 g, 6.28 mmol, 1.00 eq) in a saturated solution of KI (6.00 ml). After 20 hrs stirring at R.T., a precipitate formed 
in the orange solution, Excess iodine was quenched with 0.1 M sodium thiosulfate solution. The precipitate was filtered by 
vacuum filtration, washed with distilled H2O and dried (Na2SO4) to give the desired product as a colourless solid (1.76 g, 
6.09 mmol, quantative yield); δH (300 MHz, DMSO-d6) 1.61–1.70 (4H, m, CH2), 2.29 (2H, t, J 6.0, CH2), 2.43 (2H, s, CH2), 
CH3 under DMSO peak. Synthesis of 2-methyl-3-iodo-4-ethoxy-5,6,7,8-tetrahydroquinoline (8) Potassium carbonate 
(1.53 g, 11.1 mmol, 2.00 eq) was added to a heterogeneous mixture of 2-methyl-3-iodo-5,6,7,8-tetrahydroquinolin-4-one 
(7, 1.60 g, 5.56 mmol, 1.00 eq) in DMF (15.0 ml), and the reaction heated to 50 °C for 30 mins. The R.B. flask was removed 
from the heating mantle and ethyl iodide was added dropwise. The reaction was then heated at 50 °C for 18 hrs. The reaction 
was cooled to R.T., quenched with water (40 ml). The resulting emulsion formed which was extracted with EtOAc (50 ml). 
EtOAc layer were washed with water (3 × 30 ml), brine (3 × 30 ml), dried (Na2SO4) and concentrated to give a pale yellow 
oil (1.09 g, 3.44 mmol, 61%); Rf 0.88 (1:1 Pet–EtOAc); HPLC (RT = 1.67 mins); LCMS (Method A), (RT = 1.6 min, m/z 
(ES) Found MH+ 318.0); δH (500 MHz, CDCl3) 1.49 (3H, t, J 7.0, ethoxy CH3), 1.73–1.78 (2H, m, CH2) 1.84–1.88 (2H, 
m, CH2), 2.78–2.69 (5H, m, CH2 & CH3), 2.84 (2H, t, J 6.5, CH2), 3.97 (2H, q, J 7.0, OCH2); δC (125 MHz, CDCl3) 15.6 
(CH3), 22.3 (CH2), 22.8 (CH2), 23.6 (CH2), 29.3 (CH3), 32.0 (CH2), 68.4 (OCH2), 90.9 (Cq), 124.5 (Cq), 158.3 (Cq), 158.9 
(Cq), 163.9 (Cq). Synthesis of 2-methyl-3-(4-phenoxyphenyl)-4-ethoxy-5,6,7,8-tetrahydroquinoline (10) 2-Methyl-3-
iodo-4-ethoxy-5,6,7,8-tetrahydroquinoline (8, 0.266 g, 0.839 mmol, 1.00 eq), Pd(PPh3)4 (0.048 mg, 0.0419 mmol, 5 mol%) 
and 4-phenoxyphenylboronic acid (9, 0.270 mg, 1.26 mmol, 1.50 eq) were charged to a R.B. flask under N2(g)49. Degassed 
DMF (10.0 ml) was added to the flask followed by 2M K2CO3 (1.60 ml). The flask was heated to 85 °C under N2(g). After 
15 mins, TLC (4:1 Pet–EtOAc) confirmed reaction was complete. The reaction was cooled and diluted with EtOAc (15 ml), 
filtered through celite and partitioned between EtOAc (10 ml) and H2O (25 ml). Combined organics were washed with 
H2O (3 × 30 ml), then brine (3 × 30 ml), dried (Na2SO4) and concentrated to give a red oil which was purified by column 
chromatography (3:1 Pet–EtOAc), to give the desired product as a pale yellow oil (0.235 mg, 0.655 mmol, 78%); Rf 0.31 (3:1 
Pet–EtOAc); HPLC (RT = 3.08 mins); δH (300 MHz, CDCl3) 1.04 (3H, t, J 7.0, ethoxy CH3), 1.76–1.93 (4H, m, 2xCH2), 2.32 
(3H, s, CH3) 2.72 (2H, t, J 6.0, CH2), 2.91 (2H, t, J 6.5, CH2), 3.50 (2H, q, J 7.0, OCH2), 7.05–7.16 (5H, m, Ar-H), 7.20–7.29 
(2H, m, Ar-H), 7.31–7.43 (2H, m, Ar-H); δC (125 MHz, CDCl3) 15.7 (CH3), 22.5 (CH2), 23.0 (CH3), 23.3 (CH2), 23.4 (CH2), 
32.7 (CH2), 68.2 (OCH2), 118.6 (CH), 118.9 (CH), 123.4 (CH), 126.8 (Cq), 129.8 (CH), 131.5 (CH), 154.9 (Cq), 156.5 (Cq), 
157.1 (Cq), 157.3 (Cq); m/z (ES) (Found: MH+, 360.1973. C24H26NO2 requires MH, 360.1964). Synthesis of 2-methyl-
3-(4-phenoxyphenyl)-4-ethoxy-5,6,7,8-tetrahydroquinoline (MJM170, 4)49 Aqueous hydrobromic acid (> 48%) 
(1.00 ml) was added to a solution of 2-methyl-3-(4-phenoxyphenyl)-4-ethoxy-5,6,7,8-tetrahydroquinoline (10, 0.226 mg, 
0.630 mmol, 1.00 eq) in glacial acetic acid (2 ml). The reaction was stirred at 90 °C for 5 days, monitoring by LMCS. The 
reaction was cooled to R.T. and the pH adjusted to pH5 with 2M NaOH. The precipitate was collected by vacuum filtration 
and recrystallized from MeOH:H2O to give the desired product as an off-white solid (0.155 g, 0.467 mmol, 74%); HPLC 
(RT = 2.56 mins); δH (500 MHz, DMSO-d6) 1.66–1.72 (4H, m, 2xCH2), 2.08 (3H, s, CH3) 2.31 (2H, t, J 6.0, CH2), 2.56 (2H, t, 
J 6.0, CH2), 6.99 (2H, d, J 8.5, Ar-H), 7.06 (2H, d, J 7.5, Ar-H), 7.14–7.18 (3H, m, Ar-H), 7.40–7.43 (2H, m, Ar-H), 11.0 (1H, 
s, NH); δC (125 MHz, DMSO-d6) 17.7 (CH3), 21.5 (CH2), 21.8 (CH2), 21.9 (CH2), 26.2 (CH2), 117.8 (CH), 118.6 (CH), 121.2 
(Cq), 123.3 (CH), 123.7 (Cq), 130.0 (CH), 131.4 (Cq), 132.3 (CH), 142.3 (Cq), 143.2 (Cq), 155.0 (Cq), 156.8 (Cq), 175.4 
(Cq); m/z (ES) (Found: MH+, 332.1654. C22H22NO2 requires MH, 332.1645).
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compounds were added to making various concentrations of the drug, to a total volume of 0.5 mL. Two wells were 
filled with media only, as a control. Plates were returned to the 37 °C incubator for 72 hours.
Efficacy was determined following fixation. Staining was used to determine the numbers of cysts in cultures 
without and with treatment with the test compounds. Cells were fixed using 4% paraformaldehyde and stained 
with Fluorescein-labeled Dolichos Biflorus Agglutinin, DAPI, and anti-BAG1, and anti-SAG1. Disks were 
removed and mounted onto glass slides and visualized using microscopy (Nikon Tl7). Slides were also scanned 
using a CRi Pannoramic Scan Whole Slide Scanner and viewed using Pannoramic Viewer Software.
When cysts that had dolichos in their cyst wall were eliminated or markedly reduced in size and number, a 
compound was considered efficacious against bradyzoites in cysts.
Statistical Analyses. Significance of differences were determined using Student’s t-test. P < 0.05 was considered 
significant. Every experiment was replicated at least twice S12–15;S18,19.
A Pearson test was used to confirm a correlation between increasing dose and increasing inhibition. An 
ANOVA and subsequent pair wise comparison with Dunnett correction was used to determine whether or not 
inhibition or toxicity at a given concentration was statistically significant. Stata/SE 12.1 was used for this analysis.
This study was approved by the University of Chicago IRB, IBC, and IACUC.
In vivo Analysis (mice and zebra fish)
Initial screening with tachyzoites using IVIS, fluorescence, and histopathologyS12–15;S59–62. 
Ability of compounds to abrogate tachyzoites multiplication was assessed using an in vivo imaging system (IVIS). 
To facilitate this we have T. gondii strains from each of the 3 major lineages expressing the luciferase gene. In these 
studies mice are injected intraperitoneally with tachyzoites and parasite proliferation followed up to 30 days post 
infection. Removal of brains at 30 days allows parasite quantitation by bioluminescence ex vivo using the IVIS. 
As an alternative method to improve screening efficiency and scalability it is possible for initial screening to use 
zebrafish with histopathology and visualization as shown in Fig. 3. Quantitation also was performed using QT 
PCR as described for mice or in translucent Casper zebrafish with parasites with fluors or luciferase to screen 
rapidly. Tachyzoites and bradyzoites in cysts were used for IP infection and compounds given intraperitoneally.
Type II parasites. To test type II parasites, we used T. gondii Me49 and Prugniaud parasitesS28,S39.
Encephalitis. The ability of compounds to reduce cyst burden and prevent encephalitis induced by the Type 
II strain of T. gondii were tested. Encephalitis was assessed by histological analyses and parasite burdens evaluated 
by quantitation of cystsS59.
Oocyst induced diseaseS39. The oocyst challenge model is ideal for this study because oocysts can be 
diluted at one time and stored at 4 °C for 12 months without loss of infectivity titer. For treatment of chronic 
infection there were 5 to 10 mice per group treated 2 months after infection was established by compound in 
DMSO for parenteral administration administered once per day. Treatment was for 17 days.
Zebrafish. Zebrafish were acclimatized to 37 degrees a degree a day and then infected with tachyzoites or 
cysts of RH YFP, Me49, Veg T. gondii as describedS62. The use of RH YFP was performed for the first time herein in 
order to develop a rapidly scalable assay for drug development. This is the initial demonstration of cyst formation 
by 10 days in Zebrafish.
Tissue processing and histopathology. All organs including eyes and brains were fixed in 0.1 M phos-
phate buffer (pH 7.4) containing 4% formaldehyde. Sections were cut from paraffin-embedded tissues and stained 
with Hematoxylin and Eosin (H&E) or immunoperoxidase stained. All sections were examined and assessed 
without knowledge of the group from which they originatedS39.
Testing of cytochrome b Qi mutant yeast
Target Validation with Mutant S. cerevisiae (Growth Inhibition)S63–73. Three S. cerevisiae strains 
were used: M221Q and M221F cytochrome b mutants and wild type. They share the same nuclear genetic back-
ground deriving from AD1–9 (kindly given by M.Ghislain, UCL, Belgium). AD1–9 harbors multiple deletions in 
the ABC transporter genes that render the strain more sensitive to drugs than standard yeast strainsS65.
Cytochrome b mutant M221F was generated by mitochondrial transformation as describedS65. M221Q was 
selected as suppressor from a respiratory deficient mutantS68. Analysis of revertants from respiratory deficient 
mutants within the center N of cytochrome b in Saccharomyces cerevisiae.
Protocol fromS68: Yeast strains were grown over 48 hours at 33 °C in liquid YPG medium [1% yeast extract, 
2%(wt/vol) peptone, and 3%(vol/vol) (glycerol). Cultures were diluted to an OD600 of 0.05 and grown for 2 hrs. 
Cultures were then combined with YPG containing 6% melted agar for a total volume of 15–20 mL and poured 
onto OmniTray single-well rectangular plates that measured 86 mm by 128 mm (ThermoScientific) . Filter paper 
disks (7 mm diameter, 3 um thick) were placed onto the cooled agar plates. Compounds were dissolved in DMSO 
in diluted concentrations (1 mM, 500 μ M, 100 μ M, and 10 μ M) and 10 microliters were applied to a disk. A single 
disk with DMSO on each plate was used as a control. Plates were incubated at 33 °C. Images were obtained after 
4 days using GelDoc XR Imaging System (BioRad) and Quantity One software. Drug effect was assessed by the 
presence and size of a zone of inhibition around the disks.
Testing of P. falciparum. D6 is a drug sensitive strain from Sierra Leone, C235 is a multi-drug resistant 
strain from Thailand, W2 is a chloroquine resistant strain from Thailand, and C2B has resistance to a variety of 
drugs including atovaquone. These assays were performed as describedS74.
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Testing of P. falciparum cytochrome b Qi and DHODH mutants and drug combinations for 
P. falciparum. Parasite Strains and Culture Maintenance. We used the following parasite line from the MR4 
repository of the American Type Culture Collection (ATCC): Dd2 (MRA-156). Mutant Dd2 parasites harboring 
a G33A or G33V substitution in cytochrome b were as reportedS77. Dd2 parasites with a G131S mutation in 
cytochrome b and transgenic lines expressing a chromosomally integrated copy of the S. cerevisiae DHODH were 
utilized as previously describedS78. Parasites were cultured by standard methods in RPMI media supplemented 
with 5% human O+ serum and 0.25% AlbuMAX® II (Life Technologies 11021–045)S79.
In vitro drug sensitivity and EC50 determinations. Drug susceptibility was measured using the SYBR 
Green methodS75. Twelve point curves based on 2-fold dilutions of the test compound were carried out in tripli-
cate each day and replicated on at least three different days. EC50 values were calculated using a nonlinear regres-
sion curve fit in Prism 6.0 for Mac (GraphPad Software, Inc.).
Studies of compound, drug combinations in vitro. Isobologram experiments were performed in similar fash-
ion utilizing the modified fixed ratio methodologyS76. Briefly, MJM170 and either atovaquone or cycloguanil or 
BRD6323S79 were mixed at multiple fixed volumetric ratios (10:0, 8:2, 6:4, 4:6, 2:8, and 0:10) and then serially 
diluted in 12-point 2-fold dilutions and dispensed in triplicate to 384-well assay plates and replicated on three 
different days. EC50 values were calculated as above, and FICs were calculated for each drug combination as 
describedS76. Synergy was defined as an FIC < 1.0, additivity as FIC = 1.0, and antagonism as FIC > 1.0.
Molecular Modelling/Chemogenomics. X-ray structures of the cytochrome bc1 complex are available from 
the Protein DataBankS80. A homology model of the T. gondii cytochrome bc1 complex was generated using 
the PhyreS81 webserver. Molecular modelling and docking was performed on high performance Linux clusters 
at the University of Leeds, using specialist software: SPROUTS82 & eHiTsS83 (SymBioSis), Maestro & GlideS84 
(Schrodinger), AutoDockS84 (Scripps Institute), ROCS/EONS85 & VIDAS86 (OpenEye) and the Marvin/JChem 
suites (ChemAxon)S87.
X-ray crystallography. Cytochrome bc1 was purified as previously describedS88. Crude bovine mitochon-
dria were isolated from fresh cow heart and solubilised in DDM. The solution was clarified by ultracentrifuga-
tion at 200,000 g for 1 hour at 4 °C and the supernatant applied to a DEAE CL-6B sepharose column ca. 50 ml 
pre-equilibrated in 50 mM KPi (pH 7.5), 250 mM NaCl, 3 mM NaN3, 0.1 g/L DDM, washed with two CV and 
eluted along a gradient from 250 mM to 500 mM NaCl. Cyt. bc1 containing fractions were pooled and concen-
trated before loading on a Sepharose S300 column ca. 120 ml equilibrated with 20 mM KMOPS (pH 7.2), 100 mM 
NaCl, 0.5 mM EDTA, 0.1 g/L DDM at 0.5 ml/min. 10 mM MJM170 stock in DMSO was added to the eluted 
protein in a two-fold molar excess and allowed to incubate at 4 °C for 1 hour. Increasing amounts of PEG4000 
were then added to precipitate cyt. bc1 and separate remaining contaminants. The cyt. bc1 was then resuspended 
before buffer exchange into a final buffer (25 mM KPi (pH 7.5), 3 mM NaN3, 0.015% DDM) and concentrated 
to 40 mg/ml. 1.6% HECAMEG was added to the protein solution prior to crystals growing by the hanging drop 
vapour diffusion method against a reservoir of 50 mM KPi (pH 6.8), 100 mM NaCl, 3 mM NaN3, 9% PEG4000, 
0.16% HECMAEG. Crystals were flash frozen in 23% glycerol in reservoir solution as a cryoprotectant. Multiple 
wedges of data were collected at 100K from different points on the same crystal at I24 Diamond Light Source 
using 0.9686 Å X-rays with a Pilatus3 6M detector .
Datasets were processed in iMosflm and combined using BlendS89 to produce a complete merged dataset. 
Refinement was carried out with RefmacS91 using ProsmartS90 to generate secondary structure restraints to assist 
in the low-resolution refinement. The ligand MJM170 was produced using JLigandS92 and modelled in the Qi site 
of cyt. bc1 using CootS93. Cycles of alternating Refmac5 and manual modelling resulted in a completed model. 
Data collection and refinement statistics are summarised In Table 1. For 3715 residues 95.2% are Ramachandran 
favored, 4.6% allowed and 0.3% outliers.
Interpretation of Data and Statistical Analyses
Sample size and number of experiments. There were 3 replicate samples per group for in vitro exper-
iments. All experiments were performed with sufficient sample sizes to have an 80% power to detect differences 
at the 5% level of significance.
Statistics. Groups included untreated or mock treated controls. Results were compared using students T test, 
Chi square analysis or Fisher’s exact test as appropriate for the data set. When there were more than two groups, 
pairwise comparisons were made only when F-test for the ANOVA was significant at the 5% levels using pro-
tected least significant difference (LSD) test approach.
These methods were utilized to address the clinical problems presented in human toxoplasmosisS94–S113
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